Pomp Investments investor Anthony Pompliano discusses the likelihood of a Bitcoin boom on 'The Claman Countdown.' The ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs ...